Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Chemotherapy-induced nausea and vomiting are serious side effects of cancer treatment that
can have a significant negative impact on a patient's quality of life. Although the
prevalence of nausea and vomiting has significantly decreased due to the implementation of
new antiemetic drugs, several studies revealed that approximately 30% to 60% of patients
still complain of acute or delayed chemotherapy-induced emesis. It is estimated that slow
infusion of ondansetron in combination with dexamethasone can provide long-lasting stable
concentrations of drugs in the blood serum contributing to better effect development.
Therefore, we suggest a continuous infusion of the above-mentioned drug combination as an
alternative with potential superior activity.